Novavax Takes Accelerated Approval Pathway For Flu Vaccine Development

Novavax, Inc. (NASDAQ: NVAX) shares were seeing strong upward momentum Thursday in reaction to announcements from the company tied to the development of its NanoFlu vaccine candidate and the lease of product development and manufacturing facilities.